SCA
NKTR icon

Strategic Capital Alternatives’s Nektar Therapeutics NKTR Stock Holding History

Strategic Capital Alternatives’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-67
Closed -$11K – 411
2015
Q2 		$11K Hold
67
– – ﹤0.01% 455
2015
Q1 		$11K Buy
+67
New +$13.8K ﹤0.01% 281

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Strategic Capital Alternatives's NKTR Position: Q3 2015 in Review

Strategic Capital Alternatives sold out of Nektar Therapeutics (NKTR) in Q3 2015, closing a stake of 67 shares — an estimated $11K sold.

Strategic Capital Alternatives first reported a position in NKTR in Q1 2015 and held it in 2 quarters. The position peaked at $11K in Q2 2015. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

  • Strategic Capital Alternatives reported no remaining Nektar Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Strategic Capital Alternatives sold 67 Nektar Therapeutics shares in Q3 2015, an estimated $11K.
  • Strategic Capital Alternatives first reported a position in Nektar Therapeutics in Q1 2015 and held it in 2 quarters.
  • Strategic Capital Alternatives's Nektar Therapeutics position peaked at $11K in Q2 2015.
  • 166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.